Susan J Knox

Summary

Affiliation: Stanford University
Country: USA

Publications

  1. ncbi request reprint A novel antiangiogenesis therapy using an integrin antagonist or anti-Flk-1 antibody coated 90Y-labeled nanoparticles
    Lingyun Li
    Department of Radiation Oncology, Stanford University, CA, USA
    Int J Radiat Oncol Biol Phys 58:1215-27. 2004
  2. doi request reprint Anti-tumor and radiosensitization activities of the iron chelator HDp44mT are mediated by effects on intracellular redox status
    Junqiang Tian
    Department of Radiation Oncology, Stanford University, Stanford, CA 94305, USA
    Cancer Lett 298:231-7. 2010
  3. ncbi request reprint Anti-integrin monoclonal antibody CNTO 95 enhances the therapeutic efficacy of fractionated radiation therapy in vivo
    Shoucheng Ning
    Department of Radiation Oncology, Stanford University Medical Center, 269 Campus Drive West, CCSR 1245, Stanford, CA 94305 5152, USA
    Mol Cancer Ther 7:1569-78. 2008
  4. doi request reprint Sodium selenite radiosensitizes hormone-refractory prostate cancer xenograft tumors but not intestinal crypt cells in vivo
    Junqiang Tian
    Department of Radiation Oncology, School of Medicine, Stanford University, Stanford, CA 94305 5152, USA
    Int J Radiat Oncol Biol Phys 78:230-6. 2010
  5. doi request reprint Darinaparsin: solid tumor hypoxic cytotoxin and radiosensitizer
    Junqiang Tian
    Department of Radiation Oncology and Urology, School of Medicine, Stanford University, Stanford, California 94305, USA
    Clin Cancer Res 18:3366-76. 2012
  6. doi request reprint Selenite treatment inhibits LAPC-4 tumor growth and prostate-specific antigen secretion in a xenograft model of human prostate cancer
    Rumi S Bhattacharyya
    Department of Endocrinology, Stanford University, Stanford, CA, USA
    Int J Radiat Oncol Biol Phys 72:935-40. 2008
  7. ncbi request reprint Optimization of combination therapy of arsenic trioxide and fractionated radiotherapy for malignant glioma
    Shoucheng Ning
    Department of Radiation Oncology, Stanford University Medical Center, Stanford, CA 94305 1245, USA
    Int J Radiat Oncol Biol Phys 65:493-8. 2006
  8. doi request reprint Anti-alphav integrin monoclonal antibody intetumumab enhances the efficacy of radiation therapy and reduces metastasis of human cancer xenografts in nude rats
    Shoucheng Ning
    Department of Radiation Oncology, Stanford University Medical Center, Stanford, California 94305 5152, USA
    Cancer Res 70:7591-9. 2010
  9. doi request reprint Radioprotection and cell cycle arrest of intestinal epithelial cells by darinaparsin, a tumor radiosensitizer
    Junqiang Tian
    Department of Radiation Oncology, School of Medicine, Stanford University, Stanford, California
    Int J Radiat Oncol Biol Phys 87:1179-85. 2013
  10. doi request reprint Metalloporphyrin synergizes with ascorbic acid to inhibit cancer cell growth through fenton chemistry
    Junqiang Tian
    Department of Radiation Oncology, Stanford University, California 94305 5152, USA
    Cancer Biother Radiopharm 25:439-48. 2010

Collaborators

Detail Information

Publications39

  1. ncbi request reprint A novel antiangiogenesis therapy using an integrin antagonist or anti-Flk-1 antibody coated 90Y-labeled nanoparticles
    Lingyun Li
    Department of Radiation Oncology, Stanford University, CA, USA
    Int J Radiat Oncol Biol Phys 58:1215-27. 2004
    ..In the studies described here, we investigated the potential therapeutic efficacy of two three-component treatment regimens using two murine tumor models...
  2. doi request reprint Anti-tumor and radiosensitization activities of the iron chelator HDp44mT are mediated by effects on intracellular redox status
    Junqiang Tian
    Department of Radiation Oncology, Stanford University, Stanford, CA 94305, USA
    Cancer Lett 298:231-7. 2010
    ..Interestingly, this radiosensitizing effect was observed under aerobic and, to a larger extent, hypoxic conditions, suggesting its potential utility as a radiosensitizer for some radioresistant tumors...
  3. ncbi request reprint Anti-integrin monoclonal antibody CNTO 95 enhances the therapeutic efficacy of fractionated radiation therapy in vivo
    Shoucheng Ning
    Department of Radiation Oncology, Stanford University Medical Center, 269 Campus Drive West, CCSR 1245, Stanford, CA 94305 5152, USA
    Mol Cancer Ther 7:1569-78. 2008
    ..These findings are very promising and may have high translational relevance for the treatment of patients with solid tumors...
  4. doi request reprint Sodium selenite radiosensitizes hormone-refractory prostate cancer xenograft tumors but not intestinal crypt cells in vivo
    Junqiang Tian
    Department of Radiation Oncology, School of Medicine, Stanford University, Stanford, CA 94305 5152, USA
    Int J Radiat Oncol Biol Phys 78:230-6. 2010
    ..In this study we further evaluated the in vivo radiosensitizing effect of SSE in prostate cancer xenograft tumors and normal radiosensitive intestinal crypt cells...
  5. doi request reprint Darinaparsin: solid tumor hypoxic cytotoxin and radiosensitizer
    Junqiang Tian
    Department of Radiation Oncology and Urology, School of Medicine, Stanford University, Stanford, California 94305, USA
    Clin Cancer Res 18:3366-76. 2012
    ..Here, we studied the effects of darinaparsin (an arsenic cytotoxin) on survival and radiosensitivity of tumor cells in vitro under normoxia and hypoxia and in vivo using xenograft models, compared to effects on normal tissues...
  6. doi request reprint Selenite treatment inhibits LAPC-4 tumor growth and prostate-specific antigen secretion in a xenograft model of human prostate cancer
    Rumi S Bhattacharyya
    Department of Endocrinology, Stanford University, Stanford, CA, USA
    Int J Radiat Oncol Biol Phys 72:935-40. 2008
    ..In this study, we investigated the in vivo effects of selenite as a therapy to treat mice with established LAPC-4 tumors...
  7. ncbi request reprint Optimization of combination therapy of arsenic trioxide and fractionated radiotherapy for malignant glioma
    Shoucheng Ning
    Department of Radiation Oncology, Stanford University Medical Center, Stanford, CA 94305 1245, USA
    Int J Radiat Oncol Biol Phys 65:493-8. 2006
    ..The primary objective was to optimize the combined treatment regimen using arsenic trioxide (ATO) and fractionated radiotherapy for the treatment of malignant glioma...
  8. doi request reprint Anti-alphav integrin monoclonal antibody intetumumab enhances the efficacy of radiation therapy and reduces metastasis of human cancer xenografts in nude rats
    Shoucheng Ning
    Department of Radiation Oncology, Stanford University Medical Center, Stanford, California 94305 5152, USA
    Cancer Res 70:7591-9. 2010
    ..Intetumumab can potentiate the efficacy of fractionated radiation therapy in human cancer xenograft tumors in nude rats without increased toxicity...
  9. doi request reprint Radioprotection and cell cycle arrest of intestinal epithelial cells by darinaparsin, a tumor radiosensitizer
    Junqiang Tian
    Department of Radiation Oncology, School of Medicine, Stanford University, Stanford, California
    Int J Radiat Oncol Biol Phys 87:1179-85. 2013
    ..Here we tested the DPS radiosensitizing effect in a clinically relevant model of prostate cancer and explored the radioprotective effect and mechanism of DPS on CECs...
  10. doi request reprint Metalloporphyrin synergizes with ascorbic acid to inhibit cancer cell growth through fenton chemistry
    Junqiang Tian
    Department of Radiation Oncology, Stanford University, California 94305 5152, USA
    Cancer Biother Radiopharm 25:439-48. 2010
    ..This effect was inhibited by cellular enzymes that metabolize H(2)O(2), such as catalase and glutathione peroxidase, suggesting that selective killing of cancer cells deficient in such enzymes can be achieved in vivo...
  11. doi request reprint Lanreotide promotes apoptosis and is not radioprotective in GH3 cells
    Shoucheng Ning
    Department of Radiation Oncology, Stanford University School of Medicine, Stanford University Medical Center, 875 Blake Wilbur Drive, Stanford, California 94305 5821, USA
    Endocr Relat Cancer 16:1045-55. 2009
    ..These studies demonstrate that the somatostatin analog lanreotide is not radioprotective in GH3 cells, and further studies are necessary to determine the impact of lanreotide on apoptosis...
  12. doi request reprint Impact of rituximab treatment on (90)Y-ibritumomab dosimetry for patients with non-Hodgkin lymphoma
    Sui Shen
    Department of Radiation Oncology, Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, Alabama 35294, USA
    J Nucl Med 51:150-7. 2010
    ..Comparison of the pre- and post-rituximab imaging and blood data allowed for the assessment of impact of rituximab on (90)Y-ibritumomab dosimetry...
  13. ncbi request reprint Radiobiology of radioimmunotherapy: targeting CD20 B-cell antigen in non-Hodgkin's lymphoma
    M Carmen Hernandez
    Department of Radiation Oncology, Stanford University Medical Center, 269 Campus Drive West, Stanford, CA 94305, USA
    Int J Radiat Oncol Biol Phys 59:1274-87. 2004
    ....
  14. ncbi request reprint The radioisotope contributes significantly to the activity of radioimmunotherapy
    Thomas A Davis
    Stanford University, Stanford, California, USA
    Clin Cancer Res 10:7792-8. 2004
    ....
  15. ncbi request reprint Increased cure rate of glioblastoma using concurrent therapy with radiotherapy and arsenic trioxide
    Shoucheng Ning
    Department of Radiation Oncology, Stanford University Medical Center, 269 Campus Drive W, Stanford, CA 94305 5152, USA
    Int J Radiat Oncol Biol Phys 60:197-203. 2004
    ..In an effort to increase the efficacy of therapy for GBM, we studied the efficacy of arsenic trioxide (ATO) combined with high-dose RT in GBM cells in vitro and GBM xenograft tumors in nude mice...
  16. ncbi request reprint Clinical development of radioimmunotherapy for B-cell non-Hodgkin's lymphoma
    Ruby F Meredith
    Department of Radiation Oncology, University of Alabama Medical Center, Birmingham, AL, USA
    Int J Radiat Oncol Biol Phys 66:S15-22. 2006
    ..The quality and duration of responses are greater with radioimmunotherapy when it is used earlier in the course of treatment...
  17. ncbi request reprint Novel nitric oxide generating compound glycidyl nitrate enhances the therapeutic efficacy of chemotherapy and radiotherapy
    Shoucheng Ning
    Department of Radiation Oncology, Stanford University Medical Center, Stanford, CA 94305, USA
    Biochem Biophys Res Commun 447:537-42. 2014
    ..These results suggest that GLYN is a promising new drug for use with chemotherapy and radiotherapy, and provide a compelling rationale for future studies of GLYN and related compounds...
  18. doi request reprint Dinitroazetidines are a novel class of anticancer agents and hypoxia-activated radiation sensitizers developed from highly energetic materials
    Shoucheng Ning
    Department of Radiation Oncology, Stanford University Medical Center, Stanford, CA 94305, USA
    Cancer Res 72:2600-8. 2012
    ..Taken together, our findings offer preclinical proof-of-concept for ABDNAZ as a promising new anticancer agent with a favorable toxicity profile, either as a chemotherapeutic agent or a radiosensitizer...
  19. ncbi request reprint Inhibition of androgen receptor signaling by selenite and methylseleninic acid in prostate cancer cells: two distinct mechanisms of action
    Bryan Husbeck
    Department of Radiation Oncology, Stanford University Medical Center, 300 Pasteur Drive, CA 94305, USA
    Mol Cancer Ther 5:2078-85. 2006
    ..In conclusion, we have found that selenite and MSeA disrupt AR signaling by distinct mechanisms. The inhibition of AR expression and activity by selenite occurs via a redox mechanism involving GSH, superoxide, and Sp1...
  20. ncbi request reprint Targeting integrins and PI3K/Akt-mediated signal transduction pathways enhances radiation-induced anti-angiogenesis
    Shoucheng Ning
    Department of Radiation Oncology, Stanford University Medical Center, Stanford, CA 94305 5152, USA
    Radiat Res 168:125-33. 2007
    ..These results demonstrate that combined use of ionizing radiation, cRGD and LY294002 inhibited multiple signaling transduction pathways involved in tumor angiogenesis and enhanced radiation-induced effects on vascular endothelial cells...
  21. ncbi request reprint Enhanced effectiveness of radiochemotherapy with tirapazamine by local application of electric pulses to tumors
    Peter G Maxim
    Department of Radiation Oncology, Stanford University School of Medicine, Stanford, California 94305, USA
    Radiat Res 162:185-93. 2004
    ..These results suggest that electro-pulsation of large solid tumors may be of benefit to patients treated with radiation in combination with agents that kill hypoxic cells...
  22. ncbi request reprint Redox modulation of human prostate carcinoma cells by selenite increases radiation-induced cell killing
    Bryan Husbeck
    Department of Radiation Oncology, Stanford University, Stanford, CA 94305, USA
    Free Radic Biol Med 38:50-7. 2005
    ..These data suggest that altering the redox environment of prostate cancer cells with selenite increases the apoptotic potential and sensitizes them to radiation-induced cell killing...
  23. ncbi request reprint Clinical efficacy of zanolimumab (HuMax-CD4): two phase 2 studies in refractory cutaneous T-cell lymphoma
    Youn H Kim
    Multidisciplinary Cutaneous Lymphoma Program, Stanford Comprehensive Cancer Center, 875 Blake Wilbur Drive, Stanford, CA 94305, USA
    Blood 109:4655-62. 2007
    ..The treatment was well tolerated with no dose-related toxicity other than the targeted depletion of peripheral T cells. A pivotal study has been initiated based on these findings...
  24. doi request reprint 131I-Tositumomab (Bexxar) vs. 90Y-Ibritumomab (Zevalin) therapy of low-grade refractory/relapsed non-Hodgkin lymphoma
    Andrei Iagaru
    Division of Nuclear Medicine, Stanford University Medical Center, 300 Pasteur Drive, Stanford, CA 94305, USA
    Mol Imaging Biol 12:198-203. 2010
    ..Both target CD20 receptors present on the surface of lymphocytes. We present our clinical experience with Bexxar and Zevalin in the management of low-grade refractory or relapsed NHL...
  25. ncbi request reprint The antiangiogenic agents SU5416 and SU6668 increase the antitumor effects of fractionated irradiation
    Shoucheng Ning
    Department of Radiation Oncology, Stanford University Medical Center, Stanford, California 94305 5105, USA
    Radiat Res 157:45-51. 2002
    ..The targeting of multiple tyrosine kinase receptors by SU6668 is more effective than inhibition of the Vegf receptor alone by SU5416 for the enhancement of tumor cell killing by fractionated irradiation...
  26. ncbi request reprint Darbepoietin alfa potentiates the efficacy of radiation therapy in mice with corrected or uncorrected anemia
    Shoucheng Ning
    Department of Radiation Oncology, Stanford University, Stanford, CA 94305, USA
    Cancer Res 65:284-90. 2005
    ....
  27. ncbi request reprint Phase I study of 131I-chimeric(ch) TNT-1/B monoclonal antibody for the treatment of advanced colon cancer
    Hilary Hardy Street
    Department of Radiation Oncology, Stanford University, Stanford, CA 943053, USA
    Cancer Biother Radiopharm 21:243-56. 2006
    ..The rationale for targeting areas of tumor necrosis is the observation that necrotic lesions are more abundant in cancer lesions than in surrounding tissues...
  28. pmc Characterization of direct radiation-induced immune function and molecular signaling changes in an antigen presenting cell line
    Jennifer J Parker
    Department of Chemical and Systems Biology, Stanford University, Stanford, CA, USA
    Clin Immunol 148:44-55. 2013
    ..Our results and the analytic methods are especially well suited to the study of functional changes in APC when radiation is used for immune modulation in clinical protocols...
  29. pmc Mitigation of radiation-induced dermatitis by activation of aldehyde dehydrogenase 2 using topical alda-1 in mice
    Shoucheng Ning
    Department of Radiation Oncology, Stanford University Medical Center, Stanford, California 94305, USA
    Radiat Res 178:69-74. 2012
    ..Our findings suggest that ALDH2 represents a novel target for the treatment of radiation dermatitis without reducing the benefit of radiotherapy...
  30. ncbi request reprint Clinical manifestations of noncoronary atherosclerotic vascular disease after moderate dose irradiation
    Deep A Patel
    Department of Radiation Oncology, Stanford University School of Medicine 94305 5152, and VA Palo Alto Medical Center, California, USA
    Cancer 106:718-25. 2006
    ..Noncoronary vascular disease has been observed and may relate to more moderate dose irradiation...
  31. ncbi request reprint Radiation-induced cyclooxygenase 2 up-regulation is dependent on redox status in prostate cancer cells
    Lingyun Li
    Department of Radiation Oncology, Stanford University, School of Medicine, Stanford, California, USA
    Radiat Res 160:617-21. 2003
    ..Radiation-induced increases in ROS levels contribute to the adaptive response of PC-3 cells, resulting in elevated levels of COX2...
  32. ncbi request reprint Radiobiology of radioimmunotherapy with 90Y ibritumomab tiuxetan (Zevalin)
    M Carmen Hernandez
    Department of Radiation Oncology, Stanford University Medical Center, CA 94305, USA
    Semin Oncol 30:6-10. 2003
    ....
  33. ncbi request reprint Enhancement of the efficacy of an antagonist of an extracellular receptor by attachment to the surface of a biocompatible carrier
    Charles A Wartchow
    Targesome Inc, Palo Alto, California 94303, USA
    Pharm Res 21:1880-5. 2004
    ..IA-DCLs were characterized in vitro, and the pharmacokinetic and antitumor properties were assessed in vivo...
  34. ncbi request reprint Expression and function of erythropoietin receptors in tumors: implications for the use of erythropoiesis-stimulating agents in cancer patients
    Angus M Sinclair
    Amgen Inc, Thousand Oaks, California, USA
    Cancer 110:477-88. 2007
    ..For this report, the authors reviewed the biology of EpoR in erythropoiesis and compared and contrasted the reported findings on the role of ESAs and EpoR in tumors...
  35. ncbi request reprint MIRD continuing education: Bystander and low dose-rate effects: are these relevant to radionuclide therapy?
    George Sgouros
    School of Medicine, Johns Hopkins University, Baltimore, Maryland, USA
    J Nucl Med 48:1683-91. 2007
    ....
  36. ncbi request reprint Re-treatment with I-131 tositumomab in patients with non-Hodgkin's lymphoma who had previously responded to I-131 tositumomab
    Mark S Kaminski
    University of Michigan Comprehensive Cancer Center, Ann Arbor, USA
    J Clin Oncol 23:7985-93. 2005
    ..To study efficacy and safety of re-treatment with I-131 tositumomab in patients with low-grade, follicular, or transformed low-grade B-cell lymphoma who relapsed following a response to I-131 tositumomab...
  37. ncbi request reprint Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomas
    Richard I Fisher
    University of Rochester School of Medicine, James P Wilmot Cancer Center, 601 Elmwood Ave, Box 704, Rochester, NY 14642, USA
    J Clin Oncol 23:7565-73. 2005
    ....
  38. ncbi request reprint Distribution of monoclonal antiferritin antibody in Kaposi's sarcoma, Hodgkin's disease, and hepatocellular carcinoma
    Alan R Yuen
    Departments of Medicine, Pathology, and Radiation Oncology, Stanford University School of Medicine, Stanford, CA 94305, USA
    Hum Pathol 34:381-4. 2003
    ..One hepatocellular carcinoma showed diffuse cytoplasmic staining with ferritin. Deposition of the monoclonal antibody was not detectable in the remaining hepatocellular carcinoma samples...
  39. ncbi request reprint Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine I131 tositumomab
    John M Bennett
    James P Wilmot Cancer Center, University of Rochester School of Medicine, Rochester, NY 14642, USA
    Blood 105:4576-82. 2005
    ..With a median follow-up approaching 5 years, no case of tMDS/tAML has been reported in any of the 76 patients receiving iodine I(131) tositumomab as their initial therapy (P = .011 compared with previously treated patients)...